Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from efavirenz to lopinavir/ritonavir for persistent HIV-associated lipoatrophy
2009-010611-33Phase 4Active
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Jun 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of lopinavir, ritonavir and efavirenz in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Absolute change in extremity fat mass at 24 months. Started Jun 2009; status: active.
02
Drugs
lopinavirritonavirefavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2009-010611-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010611-33.